1. Home
  2. SYBT vs MESO Comparison

SYBT vs MESO Comparison

Compare SYBT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stock Yards Bancorp Inc.

SYBT

Stock Yards Bancorp Inc.

HOLD

Current Price

$72.39

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.68

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYBT
MESO
Founded
1904
2004
Country
United States
Australia
Employees
N/A
81
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
SYBT
MESO
Price
$72.39
$15.68
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$76.00
N/A
AVG Volume (30 Days)
137.9K
199.5K
Earning Date
04-22-2026
02-26-2026
Dividend Yield
1.81%
N/A
EPS Growth
22.11
N/A
EPS
4.75
N/A
Revenue
$23,406,000.00
N/A
Revenue This Year
$17.31
$629.74
Revenue Next Year
$9.32
$30.65
P/E Ratio
$14.95
N/A
Revenue Growth
3.37
N/A
52 Week Low
$61.51
$9.88
52 Week High
$83.83
$21.50

Technical Indicators

Market Signals
Indicator
SYBT
MESO
Relative Strength Index (RSI) 60.93 52.51
Support Level $72.29 $15.62
Resistance Level $73.79 $16.37
Average True Range (ATR) 1.82 0.39
MACD -0.06 0.01
Stochastic Oscillator 64.64 51.72

Price Performance

Historical Comparison
SYBT
MESO

About SYBT Stock Yards Bancorp Inc.

Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: